Ervebo
Phase 3Biologic
Ervebo is one of 44 biologic programs targeting Immunity. It is currently in Phase 3.
3
Indications
4
Total Trials
3
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
27 competitors in Prophylaxis
#DrugCompanyPhaseTrials
1Eliquis
Bristol-Myers SquibbApproved
Cymbalta
Jazz PharmaceuticalsApproved
Coreg
Akero TherapeuticsApproved
Xarelto
WWim Janssens
Approved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Lovenox
SanofiPhase 3
Cabenuva
GSKPhase 3
Bayer Aspirin
BayerPhase 3
Lovenox
SanofiPhase 3
Prevymis
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Immune Response1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ervebo. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details